Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Blood (2020) 136 (Supplement 1): 49–51.

https://doi.org/10.1182/blood-2020-136922

Published: 2020

Journal Articles

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

David J Young, MDPhD, Xing Fan, MD, Emma Groarke, MD, Bhavisha A Patel, MD, Ronan Desmond, MD, Thomas Winkler, MD, Andre Larochelle, MD PhD, Katherine R. Calvo, MD PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141375

Published: 2020

Journal Articles

A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages

Xing Fan, MD, David Young, MD, Thomas Winkler, MD, Zahra Pakbaz, MD, Stephanie Sellers, Ma Evette Barranta, Cynthia E. Dunbar, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138577

Published: 2020

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Daisuke Araki, MD, Ma Evette Barranta, Fariba Chinian, MS, Julie Erb-Alvarez, MPH, Thomas Winkler, MD, Neelam Giri, MD, Andre Larochelle, MD PhD

Blood (2019) 134 (Supplement_1): 3753.

https://doi.org/10.1182/blood-2019-123151

Published: 2019

Journal Articles

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 4254.

https://doi.org/10.1182/blood-2019-123946

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells

Francis Guitart, BA, Moonjung Jung, MD, Stefan Cordes, MD PhD, Shiqin Yu, Jizhong Zou, So Gun Hong, PhD, Vinh Dang, Diego A Espinoza, BA, Amy Hsu, Steven M. Holland, MD, Danielle M. Townsley, MD MSc, Cynthia E. Dunbar, MD, Thomas Winkler, MD

Blood (2018) 132 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2018-99-118410

Published: 2018

Journal Articles

Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

Alana Vicente, MD, Fernanda Gutierrez-Rodrigues, PhD, Valentina Giudice, MD, Zhijie Wu, MD PhD, Sachiko Kajigaya, PhD, Maria del Pilar Fernandez Ibanez, Maher Albitar, MD, Barbara Weinstein, RN, Katherine R. Calvo, MD PhD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Cynthia E. Dunbar, MD, Neal S. Young, MD, Thomas Winkler, MD

Blood (2018) 132 (Supplement 1): 229.

https://doi.org/10.1182/blood-2018-99-119780

Published: 2018

Journal Articles

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Xing Fan, MD, Thomas Winkler, MD, Ronan Desmond, MD, Bogdan Dumitriu, MD, Danielle M. Townsley, MD MSc, Maria del Pilar Fernandez Ibanez, Fernanda Gutierrez-Rodrigues, PhD, Sophia Grasmeder, RN, Ma Evette Barranta, Diane Madey, Jennifer Lotter, Janet Valdez, Katherine R. Calvo, MD PhD, Colin Wu, PhD, Neal S. Young, MD, Cynthia E. Dunbar, MD

Blood (2018) 132 (Supplement 1): 538.

https://doi.org/10.1182/blood-2018-99-112994

Published: 2018

Journal Articles

A Non-Human Primate CRISPR/Cas9 Model of Clonal Hematopoiesis of Indeterminate Potential Demonstrates Expansion of TET2-Disrupted Clones

Kyung-Rok Yu, PhD, Cynthia E Dunbar, MD, Marcus Corat, Shirley Chen, Aisha Aljanahi, Eun Jung Baek, Jean-Yves Metais, Hannah Natanson, Thomas Winkler, MD, Robert E Donahue, VMD

Blood (2017) 130 (Supplement 1): 117.

https://doi.org/10.1182/blood.V130.Suppl_1.117.117

Published: 2017

Journal Articles

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Thomas Winkler, MD, James N. Cooper, MD, Danielle M. Townsley, MDMSc, Phillip Scheinberg, MD, Sophia Grasmeder, RN, Colin Wu, PhD, Jennifer Lotter, Marie J Desierto, MS, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Katherine R Calvo, MD PhD, Neal S. Young, MD, Cynthia E Dunbar, MD

Blood (2017) 130 (Supplement 1): 777.

https://doi.org/10.1182/blood.V130.Suppl_1.777.777

Published: 2017

Journal Articles

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

Thomas Winkler, MD, Danielle Townsley, MD, Ronan Desmond, MD FRCPath, Bogdan Dumitriu, MD, Sophia Grasmeder, RN, BSN, OCN, Neal S. Young, Cynthia E. Dunbar, MD

Blood (2016) 128 (22): 2682.

https://doi.org/10.1182/blood.V128.22.2682.2682

Published: 2016

Journal Articles

Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression

Danielle M. Townsley, MD, James N. Cooper, MD, Thomas Winkler, MD, Phillip Scheinberg, MD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, Jennifer Lotter, Marie J. Desierto, BS, Maria del Pilar Fernandez Ibanez, MS, Colin Wu, PhD, Cynthia E. Dunbar, MD, Wanlong Ma, BS, Maher Albitar, MD, Neal S. Young

Blood (2016) 128 (22): 727.

https://doi.org/10.1182/blood.V128.22.727.727

Published: 2016

Journal Articles

More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells

Naoya Uchida, Fujita Atsushi, Haro-Mora J Juan, Thomas Winkler, MD, John F Tisdale, MD

Blood (2015) 126 (23): 1150.

https://doi.org/10.1182/blood.V126.23.1150.1150

Published: 2015

Journal Articles

Insights into Clonal Relationships of Putative Adaptive Natural Killer Cells (NK) in Humans, Via Mapping of Somatic Piga Mutations in Patients with Paroxysmal Nocturna Hemoglobinuria (PNH)

Thomas Winkler, MD, Marcus A.F. Corat, PhD, Delong Liu, PhD, Moonjung Jung, MD, Danielle M. Townsley, MD, Chuanfeng Wu, PhD, Neal S Young, MD, Cynthia E. Dunbar, MD

Blood (2015) 126 (23): 2223.

https://doi.org/10.1182/blood.V126.23.2223.2223

Published: 2015

Journal Articles

Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery

Xin Zhao, MD PhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Thomas Winkler, MD, Ronan Desmond, MD, Matthew J. Olnes, MD PhD, Harshraj Leuva, Bogdan Dumitriu, MD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): 3609.

https://doi.org/10.1182/blood.V126.23.3609.3609

Published: 2015

Journal Articles

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Danielle M. Townsley, MD, Bogdan Dumitriu, MD, Phillip Scheinberg, MD, Ronan Desmond, MD, FRCPath, Xingmin Feng, PhD, Olga Rios, RN, Barbara Weinstein, RN, Janet Valdez, PA-C, Thomas Winkler, MD, Marie Desierto, BS, Harshraj Leuva, MBBS, Colin Wu, PhD, Katherine R. Calvo, MD, PhD, Andre Larochelle, MD, PhD, Cynthia E. Dunbar, MD, Neal S. Young, MD

Blood (2015) 126 (23): LBA-2.

https://doi.org/10.1182/blood.V126.23.LBA-2.LBA-2

Published: 2015

Journal Articles

Specific Impaired CD56+ NK Cell Development in GATA2 Deficiency As Revealed By Ex Vivo NK Expansion

Moonjung Jung, MD, Jan K. Davidson-Moncada, MD PhD, Chuanfeng Wu, PhD, Samson Koelle, BA, Thomas Winkler, MD, Danielle M. Townsley, MD, Amy Hsu, BS, Keyvan Keyvanfar, BS, Steven M. Holland, MD, Dennis D. Hickstein, MD, Richard W. Childs, MD, Cynthia E. Dunbar, MD

Blood (2014) 124 (21): 1419.

https://doi.org/10.1182/blood.V124.21.1419.1419

Published: 2014

NARROW

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron

A Diamond-Blackfan Anemia Patient's Response to Eltrombopag and Genomic Analysis in Different Lineages

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Phase II Study of Eltrombopag in Subjects with Fanconi Anemia

Ivosidenib (AG-120) in Patients with IDH1 -Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Single Cell Transcriptome Analysis of GATA2 Deficiency in Hematopoiesis Modeled with Induced Pluripotent Stem Cells

Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

A Non-Human Primate CRISPR/Cas9 Model of Clonal Hematopoiesis of Indeterminate Potential Demonstrates Expansion of TET2-Disrupted Clones

Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Successful Treatment of a Diamond-Blackfan Anemia (DBA) Patient with Eltrombopag

Myeloid Neoplasm Gene Somatic Mutations in Patients with Severe Aplastic Anemia Treated with Eltrombopag and Standard Immunosuppression

More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells

Insights into Clonal Relationships of Putative Adaptive Natural Killer Cells (NK) in Humans, Via Mapping of Somatic Piga Mutations in Patients with Paroxysmal Nocturna Hemoglobinuria (PNH)

Persistent Elevation of Plasma Thrombopoietin Levels in Severe Aplastic Anemia, Even with Hematologic Recovery

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Accelerates Count Recovery and Increases Response Rates

Specific Impaired CD56+ NK Cell Development in GATA2 Deficiency As Revealed By Ex Vivo NK Expansion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only